The development of α 1a-adrenergic receptor (AR) subtype-selective antagonists is likely to
result in uroselective agents that effectively treat benign prostatic hyperplasia (BPH) …

KMD-3213, an α1a-adrenoceptor (AR) antagonist, is under development for the treatment of
urinary outlet obstruction in patients with benign prostatic hypertrophy. In the present study …

Publisher Summary This chapter elaborates advances made in development of α 1a
subtype selective adrenergic receptor antagonists. The use of selective α 1-adrenoceptor …

It has been hypothesized that in patients with benign prostatic hyperplasia, selective
antagonism of the α1A‐adrenoceptor‐mediated contraction of lower urinary tract tissues …

Alpha adrenoceptor antagonists have been convincingly shown to be beneficial in reducing
both subjective and objective indices of urethral obstruction in benign prostatic hyperplasia …

PURPOSE: We compared the affinities of a new alpha1-adrenoceptor (AR) antagonist, JTH-
601 with those of several alpha1-AR antagonists in human prostates and arteries …

Benign prostatic hyperplasia (BPH) is highly prevalent in the male population beyond the
age of 60. Impairment of urinary flow due to prostate enlargement gives rise to symptoms of …

PURPOSE: We provide a comprehensive overview of the role of α1-adrenergic receptors
(α1ARs) as critical mediators of lower urinary tract symptoms (LUTS) and pathophysiology in …

α1-Adrenoceptor (AR) antagonists are widely used for the relief of urinary retention
secondary to benign prostatic hyperplasia (BPH). While the five Food and Drug …

The present study, investigates the effect of RBx 6198, 2-{3-[4-(2-Isopropoxy-phenyl)-
piperazin-1-yl]-propyl}-3a, 4, 7, 7a-tetrahydro-isoindole-1, 3,-dione, a novel α1-adrenoceptor …